Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare ultra-long-acting insulin degludec with glargine for efficacy and safety in insulin-naive patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs (OADs). RESEARCH DESIGN AND METHODS: In this 1-year, parallel-group, randomized, open-label, treat-to-target trial, adults with type 2 diabetes with A1C of 7−10% taking OADs were randomized 3:1 to receive once daily degludec or glargine, both with metformin. Insulin was titrated to achieve prebreakfast plasma glucose (PG) of 3.9−4.9 mmol/L. The primary end point was confirmation of noninferiority of degludec to glargine in A1C reduction after 52 weeks in an intent-to-treat analysis. RESULTS: In all, 1,030 participants (mean age 59 years; baseline A1C 8.2%) were randomized (degludec 773, glargine 257). Reduction in A1C with degludec was similar (noninferior) to that with glargine (1.06 vs. 1.19%), with an estimated treatment difference of degludec to glargine of 0.09% (95% CI −0.04 to 0.22). Overall rates of confirmed hypoglycemia (PG <3.1 mmol/L or severe episodes requiring assistance) were similar, with degludec and glargine at 1.52 versus 1.85 episodes/patient-year of exposure (PYE). There were few episodes of nocturnal confirmed hypoglycemia in the overall population, and these occurred at a lower rate with degludec versus glargine (0.25 vs. 0.39 episodes/PYE; P = 0.038). Similar percentages of patients in both groups achieved A1C levels <7% without hypoglycemia. End-of-trial mean daily insulin doses were 0.59 and 0.60 units/kg for degludec and glargine, respectively. Adverse event rates were similar. CONCLUSIONS: Insulins degludec and glargine administered once daily in combination with OADs provided similar long-term glycemic control in insulin-naive patients with type 2 diabetes, with lower rates of nocturnal hypoglycemia with degludec.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of the phase III trials with IDeg were designed as treat-to-target trials striving for an ambitious (fasting) blood glucose level target of 4–5 mmol/L (70–90 mg/dL).”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a result of the treat-to-target design, a comparison can be made in terms of differences in endpoints such as hypoglycaemia (but not, for example, HbA1c), as illustrated in Table 4 [48–54].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“the concentration of IDeg-specific antibodies and antibodies cross-reacting with IDeg and human insulin was found to be low in studies in patients with T1DM [48, 49] or T2DM [50, 53], indicating that the risk of immunogenicity with IDeg is minimal.”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Ethical principles for medical research involving human subjects
(2003) · Manual for Research Ethics Committees · doi:10.1017/cbo9780511550089.027 · Cited by 2,585
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
(2014) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/jwiet-2014-0117 · Cited by 2,473
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Self-citationHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794 · cited 1×
“Additionally, the risk, consequences, and fear of hypoglycemia remain a significant limiting factor in intensifying insulin therapy and optimizing glycemic control (9).”
Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects
(2009) · JIBL · doi:10.1515/jibl.2009.12 · Cited by 768
Research works printed but not linked: 2
- International Diabetes foundation. Diabetes atlas 5th edition [article online], 2011. Available from http://www.idf.org/diabetesatlas/5e/the-global-burden. Accessed 10 January 2012
- Heise, 2011, The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state (Abstract), Diabetes, 60, A263
Cited by
Items 301–342 of 342
Insulin Degludec — A New Ultralong-Acting Insulin
Brett, A. S. (2013) · Journal watch · doi:10.1056/jw201301030000002
Clinical Use of New Insulins and New Insulin Delivery Systems
Lim, T., & Ko, S. (2015) · Journal of Korean Diabetes · doi:10.4093/jkd.2015.16.4.242
Risk of Insulin Accumulation (Stacking) with use of Novel Ultralong-Acting Insulin Formulation
Bansal, V., Davis, G. M., & Ismail‐Beigi, F. (2014) · Endocrine Practice · doi:10.4158/ep14144.co
Diabète de type2: insulinothérapie basale, « flat insulin for flat sugar »
Monnier, L., & Colette, C. (2017) · doi:10.1016/b978-2-294-74646-8.00012-2
Diabète de type2: échec de l'insulinothérapie basale
Monnier, L., & Colette, C. (2017) · doi:10.1016/b978-2-294-74646-8.00014-6
Chapitre 11 – Diabète de type 2 : échec des antidiabétiques oraux
Monnier, L., & Colette, C. (2017) · doi:10.1016/b978-2-294-74646-8.00011-0
Möglichkeiten und Grenzen der aktuellen Insulintherapie
Forst, T. M. (2017) · Info Diabetologie · doi:10.1007/s15034-017-0976-7
Greeff, O. B. W., van Tonder, J. J., Naidu, K., McMaster, A., van Tonder, A., & Mothilal, R. (2018) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2017.1407097
Möglichkeiten und Grenzen der aktuellen Insulintherapie: Diabetes mellitus
Forst, T. M. (2018) · CME · doi:10.1007/s11298-018-6417-7
Bailey, T. S., Odugbesan, O., Gill, J., Nikonova, E. V., Chao, J., & Reid, T. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0181
Insulintherapie beim Typ-2-Diabetes: Therapievorteil durch neue analoge Insuline?
Kreß, S. (2019) · Diabetes aktuell · doi:10.1055/a-0836-1951
12th Roche Diabetes Care Network Meeting: April 11–13, 2019, Copenhagen, Denmark
Parkin, C. G., Zepezauer, C., & Hinzmann, R. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0392
Greeff, O. B. W., van Tonder, J. J., Naidu, K., McMaster, A., van Tonder, A., & Mothilal, R. (2018) · South African Family Practice · doi:10.4102/safp.v60i4.4903
Thérapeutique des désordres glycémiques
Monnier, L., & Colette, C. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00007-x
When and how to Use Prandial Insulin with Ultralong-Acting Basal Insulin in T2Dm
Umpierrez, G. E. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42964-7
When and how to Use Ultralong-Acting Basal Insulin in T2Dm
Garber, A. J. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42963-5
When and how to Use A Glp-1 ra With Long- or Ultralong-Acting Basal Insulin in T2Dm
Bode, B. W. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42965-9
Newer Long-Acting Basal Insulin Preparations
Blonde, L. (2017) · Endocrine Practice · doi:10.1016/s1530-891x(20)43535-9
Excessive Basal Insulin Dosage When Following the Accepted Titration Method
King, A. B. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.02.017
Хусанходжаева, М. З., Rakhimova, G., & Mullabaeva, G. (2020)
Garber, A. J. (2016) · Endocrine Practice · doi:10.4158/1934-2403-22.s5.1
L’insulinothérapie chez les personnes âgées diabétiques de type 2 : l’éclairage de l’étude Gérodiab
Bauduceau, B., Bordier, L., & Doucet, J. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.07.023
Gupta, K., Deka, S., & Chandolia, B. (2022) · International Journal of Science and Healthcare Research · doi:10.52403/ijshr.20220108
Iwamoto, M., Nakanishi, S., Iwamoto, H., Kaneto, H., & Maegawa, H. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0647
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Type 2 diabetes: glycaemic control
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch10
Monnier, L., & Halimi, S. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00029-4
INTENSIVE HYPOGLYCEMIC THERAPY AS A TRIGGER FOR ELECTRICAL MYOCARDIAL INSTABILITY
Mirzarakhimova Zulfiya Khusankhodzhaevna, R. G. N. (2021) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.5585470
Session One: Basal Insulins: Still Innovating After All These Years
Michel, L. (2017) · EMJ Diabetes · doi:10.33590/emjdiabet/10311215
Davidson, M. B. (2023) · Clinical Diabetes · doi:10.2337/cd22-0106
Lee, B., Ahn, K. J., Cho, H., Lee, E. Y., Min, K. W., Dahaoui, A., Jeong, J. S., Lim, H. J., & Jang, H. C. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01448-8
Iqbal, A., Chow, E., Jones, T. W., & Heller, S. R. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch40
Kelley, D., Addison, J. D., Janzen, K. M., & Wulfe, S. (2024) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1997
Trujillo, M. E., Han, Y., Baillie, R., Weis, M. C., Chung, D., Hayes, S., Carrington, P. E., & Reed, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121522
Arentsen, M. G., Boiroux, D., Mohebbi, A., Aradóttir, T. B., Vestergaard, P., Bengtsson, H. L., & Jørgensen, J. B. (2025) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc58623.2025.11252793
Weissman, D. B., Gray, D. A., Pham, H. T., & Tijssen, P. (2012) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.210106
Tirzepatide: A Paradigm Shift in the Management of Type 2 Diabetes and Obesity
Sonawane, R. A., Gulave, O. K., Kale, P. A., & Rasal, P. B. (2026) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0092
Xue, J., Katz, M., Zhang, B., Schneck, K. B., KAZDA, C. M., & Dassau, E. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261451277
INTENSIVE HYPOGLYCEMIC THERAPY AS A TRIGGER FOR ELECTRICAL MYOCARDIAL INSTABILITY
Mirzarakhimova, Z. K., Рахимова, Г. Н., & Муллабаева, Г. У. (2021) · European journal of molecular medicine
Stüdemann, S., Gollasch, M., & Engeli, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786211
Miller, J. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00004-x
Metadata
- Authors
- Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators
- Affiliations
- Mount Sinai Hospital (CA)
- Scripps Whittier Diabetes Institute, La Jolla, California
- Centre Hospitalier Universitaire de Nantes (FR)
- Metabolic Institute of America, Tarzana, California
- Endocrine and Metabolic Consultants, Rockville, Maryland
- Novo Nordisk (Denmark) (DK)
- Universitair Ziekenhuis Leuven (BE)
- Corresponding author
- Mathieu, Chantal
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-11-14
- Volume
- 35
- Issue
- 12
- Pages
- 2464-2471
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3507614
- OpenAlex
- W1965832529
- Semantic Scholar
- d71056ccc92e22c6deda4b52fb5b27aada6b0588
- Cited by
- 336
- References
- 34
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 12 · 2023: 15 · 2022: 16 · 2021: 13 · 2020: 17 · 2019: 29 · 2018: 32 · 2017: 38 · 2016: 30 · 2015: 41 · 2014: 42 · 2013: 35 · 2012: 4
- FWCI
- 31.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Amarin Corporation
- MannKind Corporation
- Halozyme
- Novo Nordisk
- Genentech
- Merck Sharp and Dohme
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin degludec, insulin glargine, type 2 diabetes, insulin-naive patients, ultra-long-acting insulin, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, metformin, oral antidiabetic drugs, insulin dose, non-inferiority, treat-to-target, insulin dose adjustment, adverse events
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Treatment Outcome, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.